C. Rizzo

发表

Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care

L. Sequist, A. Dastur, J. Engelman, 2017, Cell reports.

Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer.

S. Digumarthy, A. Iafrate, L. Sequist, 2018, JCO precision oncology.

MET amplification (amp) as a resistance mechanism to osimertinib.

C. Azzoli, L. Sequist, A. Shaw, 2017 .

Heterogeneity and Variation in Resistance Mechanisms Among 223 Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Patients With > 1 Post-Resistance Biopsy.

S. Digumarthy, C. Azzoli, M. Mino‐Kenudson, 2017, International journal of radiation oncology, biology, physics.